Edamura K, Nasu Y, Takaishi M, Kobayashi T, Abarzua F, Sakaguchi M, Kashiwakura Y, Ebara S, Saika T, Watanabe M, Huh N-H, Kumon H
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Cancer Gene Ther. 2007 Sep;14(9):765-72. doi: 10.1038/sj.cgt.7701071. Epub 2007 Jun 29.
We had previously reported that REIC/Dkk-3, a member of the Dickkopf (Dkk) gene family, works as a tumor suppressor. In this study, we evaluated the therapeutic effects of an intratumoral injection with adenoviral vector encoding REIC/Dkk-3 gene (Ad-REIC) using an orthotopic mouse prostate cancer model of RM-9 cells. We also investigated the in vivo anti-metastatic effect and in vitro anti-invasion effect of Ad-REIC gene delivery. We demonstrated that the Ad-REIC treatment inhibited prostate cancer growth and lymph node metastasis, and prolonged mice survival in the model. These therapeutic responses were consistent with the intratumoral apoptosis induction and in vitro suppression of cell invasion/migration with reduced matrix metalloprotease-2 activity. We thus concluded that in situ Ad-REIC/Dkk-3 gene transfer may be a promising therapeutic intervention modality for the treatment of prostate cancer.
我们之前曾报道,Dickkopf(Dkk)基因家族成员REIC/Dkk-3作为一种肿瘤抑制因子发挥作用。在本研究中,我们使用RM-9细胞的原位小鼠前列腺癌模型,评估了瘤内注射编码REIC/Dkk-3基因的腺病毒载体(Ad-REIC)的治疗效果。我们还研究了Ad-REIC基因递送的体内抗转移作用和体外抗侵袭作用。我们证明,Ad-REIC治疗可抑制前列腺癌生长和淋巴结转移,并延长模型小鼠的生存期。这些治疗反应与瘤内凋亡诱导以及体外细胞侵袭/迁移抑制和基质金属蛋白酶-2活性降低相一致。因此,我们得出结论,原位Ad-REIC/Dkk-3基因转移可能是一种有前景的前列腺癌治疗干预方式。